Quarterly report pursuant to Section 13 or 15(d)

INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative)

v3.21.2
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 12, 2018
Aug. 20, 2018
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Naltrexone Implant Formulation [Member] | Trinity Compound Solutions [Member]            
Cash paid for acquisition   $ 10,000        
Aggregate purchase price, Shares   20,000        
Estimated useful lives   5 years        
Aggregate purchase price, value   $ 236,000        
Intellectual Property [Member]            
Amortization expense     $ 11,790 $ 11,790 $ 23,580 $ 23,580
Accumulated amortization     82,730   82,730  
Patents [Member]            
Amortization expense     295 $ 292 589 $ 584
Accumulated amortization     $ 11,974   $ 11,974  
Six patent families [Member]            
Estimated useful lives 13 years          
Patent acquired cost $ 15,200